These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25257248)

  • 21. Venlafaxine and O-desmethylvenlafaxine serum levels are positively associated with antidepressant response in elder depressed out-patients.
    De Donatis D; Porcelli S; Zernig G; Mercolini L; Giupponi G; Serretti A; Conca A; Florio V
    World J Biol Psychiatry; 2022 Mar; 23(3):183-190. PubMed ID: 34096828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine.
    Grözinger M; Dragicevic A; Hiemke C; Shams M; Müller MJ; Härtter S
    Pharmacopsychiatry; 2003 Jan; 36(1):3-6. PubMed ID: 12649767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine.
    Kowalewski C; Haen E; Hiemke C; Ridders F; Endres K; Gründer G; Paulzen M; Schoretsanitis G
    Int Clin Psychopharmacol; 2019 Sep; 34(5):241-246. PubMed ID: 31094902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of the CYP2D6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences.
    Sicras-Mainar A; Guijarro P; Armada B; Blanca-Tamayo M; Navarro-Artieda R
    PLoS One; 2014; 9(11):e90453. PubMed ID: 25369508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Venlafaxine's therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis.
    Lense XM; Hiemke C; Funk CSM; Havemann-Reinecke U; Hefner G; Menke A; Mössner R; Riemer TG; Scherf-Clavel M; Schoretsanitis G; Gründer G; Hart XM
    Psychopharmacology (Berl); 2024 Feb; 241(2):275-289. PubMed ID: 37857898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pharmacokinetics of venlafaxine when given in a twice-daily regimen.
    Troy SM; Parker VD; Fruncillo RJ; Chiang ST
    J Clin Pharmacol; 1995 Apr; 35(4):404-9. PubMed ID: 7650231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey.
    Hefner G; Unterecker S; Shams ME; Wolf M; Falter T; Haen E; Hiemke C
    J Neural Transm (Vienna); 2015 Nov; 122(11):1609-17. PubMed ID: 25940834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Therapeutic drug monitoring of antidepressants: Why venlafaxine is the most monitored drug? A review of literature].
    Couderc S; Mory C; Darnaud L; Saint-Marcoux F
    Therapie; 2021; 76(6):725-733. PubMed ID: 33551091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonin and Norepinephrine Reuptake Inhibitors.
    Shelton RC
    Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report.
    Eap CB; Bertel-Laubscher R; Zullino D; Amey M; Baumann P
    Pharmacopsychiatry; 2000 May; 33(3):112-5. PubMed ID: 10855463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
    Whyte EM; Romkes M; Mulsant BH; Kirshne MA; Begley AE; Reynolds CF; Pollock BG
    Int J Geriatr Psychiatry; 2006 Jun; 21(6):542-9. PubMed ID: 16642541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study).
    Lloret-Linares C; Daali Y; Chevret S; Nieto I; Molière F; Courtet P; Galtier F; Richieri RM; Morange S; Llorca PM; El-Hage W; Desmidt T; Haesebaert F; Vignaud P; Holtzmann J; Cracowski JL; Leboyer M; Yrondi A; Calvas F; Yon L; Le Corvoisier P; Doumy O; Heron K; Montange D; Davani S; Déglon J; Besson M; Desmeules J; Haffen E; Bellivier F
    BMC Pharmacol Toxicol; 2017 Nov; 18(1):70. PubMed ID: 29115994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Venlafaxine serum levels and CYP2D6 genotype.
    Veefkind AH; Haffmans PM; Hoencamp E
    Ther Drug Monit; 2000 Apr; 22(2):202-8. PubMed ID: 10774634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of analytical methods in the determination of two venlafaxine fatalities.
    Long C; Crifasi J; Maginn D; Graham M; Teas S
    J Anal Toxicol; 1997; 21(2):166-9. PubMed ID: 9083836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of CYP2D6 Genotypes on Venlafaxine Metabolism in Japanese Psychiatric Patients With Depression.
    Komahashi-Sasaki H; Yasui-Furukori N; Sasaki T; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
    Ther Drug Monit; 2021 Oct; 43(5):681-687. PubMed ID: 33306568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum level of venlafaxine is associated with better memory in psychotic disorders.
    Steen NE; Aas M; Simonsen C; Dieset I; Tesli M; Nerhus M; Gardsjord E; Mørch R; Agartz I; Melle I; Vaskinn A; Spigset O; Andreassen OA
    Schizophr Res; 2015 Dec; 169(1-3):386-392. PubMed ID: 26516101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database.
    Schoretsanitis G; Haen E; Gründer G; Hiemke C; Endres K; Ridders F; Correll CU; Paulzen M
    Eur J Clin Pharmacol; 2019 Aug; 75(8):1109-1116. PubMed ID: 30968172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYP2D6*10 polymorphism and the enantioselective O-desmethylation of S-(+)- and R-(-)-venlafaxine in Japanese psychiatric patients.
    Sasaki T; Yasui-Furukori N; Komahashi-Sasaki H; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
    Basic Clin Pharmacol Toxicol; 2021 May; 128(5):677-685. PubMed ID: 33470005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective solid-phase extraction using molecularly imprinted polymers for analysis of venlafaxine, O-desmethylvenlafaxine, and N-desmethylvenlafaxine in plasma samples by liquid chromatography-tandem mass spectrometry.
    Miranda LF; Domingues DS; Queiroz ME
    J Chromatogr A; 2016 Aug; 1458():46-53. PubMed ID: 27388659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects.
    Ciusani E; Zullino DF; Eap CB; Brawand-Amey M; Brocard M; Baumann P
    J Psychopharmacol; 2004 Dec; 18(4):559-66. PubMed ID: 15582923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.